ArticleAlzheimer's & dementia (New York, N. Y.)2019
Differential effects of neurodegeneration biomarkers on subclinical cognitive decline.
Article in Alzheimer's & dementia (New York, N. Y.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Synaptic markers are associated with cognitive decline after accounting for amyloid burden among an at-risk Alzheimer's disease cohort.Scientific reports · 2025Article
- Biofluid biomarkers for Alzheimer's disease: past, present, and future.Medical review (2021) · 2024Review
- Biomarkers for neurodegeneration impact cognitive function: a longitudinal 1-year case-control study of patients with bipolar disorder and healthy control individuals.International journal of bipolar disorders · 2024Article
- Plasma neurofilament light and brain volumetric outcomes among middle-aged urban adults.Neurobiology of aging · 2023Article
- Genome-Wide Epistasis Study of Cerebrospinal Fluid Hyperphosphorylated Tau in ADNI Cohort.Genes · 2023Article
- Associations of Neurodegeneration Biomarkers in Cerebrospinal Fluid with Markers of Alzheimer's Disease and Vascular Pathology.Journal of Alzheimer's disease : JAD · 2023Article
- BMI and Allostatic Load Are Directly Associated with Longitudinal Increase in Plasma Neurofilament Light among Urban Middle-Aged Adults.The Journal of nutrition · 2022Article
- Neurogranin and Neuronal Pentraxin Receptor as Synaptic Dysfunction Biomarkers in Alzheimer's Disease.Journal of clinical medicine · 2021Article
- Plasma neurofilament light as a potential biomarker for cognitive decline in a longitudinal study of middle-aged urban adults.Translational psychiatry · 2021Article
- Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age.Neurobiology of aging · 2021Article
- Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort.Neurology · 2021Article
- Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development.Frontiers in neurology · 2021Review
- Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies.Frontiers in neuroscience · 2021Review
- Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?Alzheimer's research & therapy · 2020Article
- Clinical Utility of the Pathogenesis-Related Proteins in Alzheimer's Disease.International journal of molecular sciences · 2020Review
- Alzheimer's disease: from basic science to precision medicine approach.BMJ neurology open · 2020Review
- Cognition at age 70: Life course predictors and associations with brain pathologies.Neurology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
introductionNeurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t-tau and alternative biomarkers of neurodegeneration-neurogranin and neurofilament light protein (NFL)-add value in predicting subclinical cognitive decline.
methodsOne hundred fifty cognitively unimpaired participants received a lumbar puncture for cerebrospinal fluid and at least two neuropsychological examinations (mean age at first visit = 59.3 ± 6.3 years; 67% female). Linear mixed effects models were used with cognitive composite scores as outcomes. Neurodegeneration interactions terms were the primary predictors of interest: age × NFL or age × neurogranin or age × t-tau. Models were compared using likelihood ratio tests.
resultsAge × NFL accounted for a significant amount of variation in longitudinal change on preclinical Alzheimer's cognitive composite scores, memory composite scores, and learning scores, whereas age × neurogranin and age × t-tau did not. DISCUSSION: These data suggest that NFL may be more sensitive to subclinical cognitive decline compared to other proposed biomarkers for neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.